Bottom line
FHLC vs FTXH: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) share a meaningful slice of their top holdings — about 51% by weight.
But FHLC is far broader, holding 337 positions to 51 for FTXH, so beyond the top names it adds exposure FTXH doesn't have.
FHLC is cheaper at 0.084% vs 0.6% — a difference of $52 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +6.5% for FTXH (reporting dates differ).
Updated Nov 19, 2026
FHLC vs FTXH side by side
| FHLC | FTXH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Fidelity | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 0.6% |
| Annual cost per $10k | $8.4 | $60 |
| 10-yr cost on $10k (prospectus) | $108 | — |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +2.6% | +24.0% |
| 5-yr return (annualized) | +7.2% | +6.5% |
| 10-yr return (annualized) | +8.8% | — |
| Best quarter | +16.4% | +18.3% |
| Worst quarter | −13.1% | −17.4% |
| Net assets (fund) | $3.3B | $36.2M |
| Number of holdings | 337 | 51 |
| Portfolio turnover | 3% | 35% |
| Returns as of | Nov 30, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | FTXH | Difference |
|---|---|---|---|
| 2024 | +2.6% | +3.0% | −0.4% |
| 2023 | +2.5% | −1.4% | +3.9% |
| 2022 | −5.5% | +2.5% | −8.0% |
| 2021 | +20.4% | +6.1% | +14.3% |
| 2020 | +18.1% | +10.9% | +7.3% |
| 2019 | +21.9% | +22.4% | −0.4% |
| 2018 | +5.5% | −8.4% | +13.9% |
| 2017 | +23.3% | +18.8% | +4.5% |
Source: Fund prospectus bar charts
Holdings overlap
11 of FHLC's top 25 holdings also appear in FTXH's top 25.
| Holding | FHLC | FTXH |
|---|---|---|
| Eli Lilly & Co | 13.35% | 7.77% |
| Johnson & Johnson | 8.93% | 6.96% |
| AbbVie Inc | 6.42% | 7.39% |
| Merck & Co Inc | 4.66% | 7.07% |
| Amgen Inc | 3.00% | 3.18% |
| Gilead Sciences Inc | 2.34% | 2.89% |
| Pfizer Inc | 2.06% | 2.97% |
| Bristol-Myers Squibb Co | 1.93% | 6.29% |
| Vertex Pharmaceuticals Inc | 1.76% | 3.41% |
| Regeneron Pharmaceuticals Inc | 1.15% | 2.72% |
| Cardinal Health Inc | 0.78% | 3.53% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between FHLC and FTXH?
Which is cheaper, FHLC or FTXH?
Should I own both FHLC and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.